Not applicable. This is an observational study.: Not applicable. This is an observational study.
Study summary
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
Eligibility
Sex
ALL
Min age
40 Years
Max age
89 Years
Healthy volunteers
No
Inclusion Criteria
* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
* BMI of ≥ 30 kg/m2 (obesity); OR
* BMI of ≥ 27 kg/m2 to \< 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Exclusion Criteria
* Pregnancy or lactation.
* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.
* Active cancer on chemotherapy or immunotherapy.
* Known hypersensitivity or contraindications to GLP-1 RAs.
* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.
Primary outcome measure(s)
LinAge2 Biological Age — Baseline and 6 months The primary outcome of this study is to determine the change in LinAge2 biological age estimates in response to the NOVI Health weight management program, which comprises GLP-1 RA therapy alongside personalized diet and physical activity interventions.
Trial sites (2)
Facility
City
Region
Status
NOVI Health (T3 Health PTE LTD)
Singapore
Singapore
National University of Singapore
Singapore
Singapore
More National University of Singapore trials in Singapore
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.